Professor Toby Maher: Profile
Professor Toby Maher has worked as Consultant Respiratory Physician on the Interstitial Lung Disease Unit at the Royal Brompton Hospital since 2009. He is also a Senior Lecturer at Imperial College, London.
The Royal Brompton Interstitial Lung Disease (ILD) Unit is dedicated to the diagnosis and treatment of patients with various forms of interstitial lung disease (this includes conditions such as idiopathic pulmonary fibrosis (IPF), sarcoidosis and lung disease associated with connective tissue disease). The unit is the longest established dedicated centre of its kind in the United Kingdom and is one of the largest ILD units in the world.
The Brompton ILD unit was involved in early trials of the new anti-fibrotic drugs pirfenidone and nintedanib.
In addition to his clinical role, Prof Maher runs a large program of research in to pulmonary fibrosis. He currently oversees a portfolio of 12 clinical trials studying new therapies for idiopathic pulmonary fibrosis and connective tissue disease associated interstitial lung disease. Dr Maher frequently lectures on topics related to pulmonary fibrosis and interstitial lung disease both in the UK and at major international meetings including in the United States
Clinical Interests:
Prof Maher’s particular areas of clinical expertise include:
Idiopathic Pulmonary Fibrosis (IPF)
Hypersensitivity pneumonitis
Sarcoidosis
Lung disorders associated with connective tissue and autoimmune diseases
Cryptogenic organising pneumonia (COP)
Why choose Toby Maher:
Prof Maher offers the latest treatments to help patients suffering with conditions such as idiopathic pulmonary fibrosis, sarcoidosis and lung disease associated with connective tissue disease. These include; pirfenidone, nintedanib and rituximab.